Fewer than 10% of patients that would benefit from GLP-1 drugs like Wegovy have access to them, caution the WHO as it publishes its first advice on the medications.
Given more than one billion individuals worldwide currently classified as obese, it is calling for more widespread and fairer access to GLP-1 medication.
Based on forecasts, over two billion will be living with obesity by 2030 if no action is taken.
"The new guidance recognises that excess weight is a lifelong illness that can be managed with holistic and ongoing support," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are key hurdles to widespread access to the jabs that can aid individuals in losing substantial body mass, notes the agency.
GLP-1 Therapy Shortage
Even under the present best projected case, the supply of these medications might only reach approximately 100 million people – fewer than 10% of the global need, according to the health organization.
The advice urges governments and firms to expand access, through measures such as licensing agreements.
A patent on the active ingredient – the core ingredient of the drug Wegovy – is due to expire in several nations in 2026.
How Obesity Drugs Work
These medications imitate a body's own hormone to reduce digestion speed, suppress the appetite and enhance feelings of fullness so users reduce food intake.
People usually begin shedding pounds within a few weeks of commencing the regular doses.
Research suggests patients may regain a significant portion after a year of halting the drug, as their normal appetite resume.
To be carrying excess weight increases your likelihood for experiencing health problems, such as type 2 diabetes, cardiovascular issues, stroke, and specific cancers.
Excess weight concerns people in every country and was responsible for over three and a half million deaths worldwide in 2024, as per the health agency.
